Read Ophthalmology Times' extensive coverage from the 2007 annual meeting in New Orleans, USA.
First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)
SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial
Higher Molar Dose and Its Translation into Clinical Practice
Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care
The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women
Advanced therapies in neovascular AMD and DMO: Experts weigh in
A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden
OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod
Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial
Renal dysfunction negatively impacts effect of diabetic macular oedema therapy
Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported
